key: cord-0984667-nqyyma8o
authors: Betancourt-del Campo, Hector; Jerjes-Sanchez, Carlos; Castillo-Perez, Mauricio; López-de la Garza, Hector; Paredes-Vázquez, José Gildardo; Flores-Sayavedra, Yoezer Z; Moreno-Abril Hoyos, Francisco; Ibarra-Flores, Marcos
title: Systemic thrombolysis and anticoagulation improved biomarker measurements in massive-like pulmonary embolism and severe COVID-19 pneumonia: a case report
date: 2020-12-13
journal: Eur Heart J Case Rep
DOI: 10.1093/ehjcr/ytaa448
sha: f7af828383e6d64583182e8daa4194c293449e41
doc_id: 984667
cord_uid: nqyyma8o

BACKGROUND: From asymptomatic patients to severe acute respiratory distress syndrome, COVID-19 has a wide range of clinical presentations, and venous thromboembolism has emerged as a critical and frequent complication. CASE SUMMARY: We present a case of a 69-year-old man with a clinical presentation of massive-like pulmonary embolism (PE) overlapping with severe COVID-19 pneumonia. The diagnosis was made based on hypotension, severe oxygen desaturation (33%), and right ventricular dysfunction (RVD). We used alteplase and low-molecular-weight heparin, obtaining immediate clinical improvement. Also, we identified an extremely elevated D-dimer (31.2 mcg/mL), and computed tomography pulmonary angiography (CTPA) revealed an unexpected low thrombus burden and a crazy-paving pattern. Considering this, we decided to discontinue the alteplase. Therefore, the mechanisms of pulmonary hypertension and RVD could be multifactorial. Despite the patient’s respiratory status worsening and ongoing mechanical ventilation, biomarkers kept lowering to normal ranges. It appears a favourable outcome was related to early PE diagnosis and a multimodal therapeutic approach. DISCUSSION: Physicians in the ER should be warned about extremely high D-dimer measurements and severe oxygen desaturation as possible markers of severe COVID-19 pneumonia in patients with high-clinical suspicion of PE. Although ESC guidelines recommend immediate reperfusion in cardiogenic shock secondary to PE, we suggest initial CTPA in patients with high-clinical suspicion of severe COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered in Wuhan, China, in late 2019, and coronavirus disease 2019 , the disease caused by SARS-CoV-2, rapidly evolved into a global pandemic. COVID-19 is characterized by high mortality predominantly in male patients secondary to severe acute respiratory distress syndrome. 1 However, among common complications observed in deceased patients with COVID-19 disease, venous thromboembolism has emerged as a critical and frequent complication. Currently, most of the data regarding this clinical association has been derived from hospitalized patients. Data on the clinical presentation, therapeutic approach, and biomarkers behaviour in outpatients are scarce. 2 Here we present the case of a 69-year-old man with a clinical presentation of massive-like pulmonary embolism (PE) overlapped with severe COVID-19 pneumonia in whom we observed immediate clinical improvement using a reduced alteplase dose. Additionally, we identified an unusual D-dimer (DD) measurement, multifactorial mechanisms of pulmonary hypertension, and upon admission, despite severe right ventricular dysfunction, a borderline B-type natriuretic peptide (BNP) value.

A 69-year-old man presented to the Emergency room (ER) with a 2-h history of stabbing pain in the right lower limb, associated with sudden dyspnoea, plus severe chest pain 6/10, presyncope, and profuse diaphoresis. His past medical history included former smoking, hypertension 

On arrival to the ER Clinical instability, oxygen desaturation (33%)

Electrocardiogram: sinus tachycardia, S1Q3T3, qR, ST-elevation in V1 and aVR Chest X-ray: bilateral ground-glass opacity 

(valsartan, hydrochlorothiazide, and atenolol), chronic obstructive pulmonary disease (non-specified treatment), obstructive sleep apnoea syndrome treated with continuous positive airway pressure (CPAP), undifferentiated arthritis (sulfasalazine and acemetacin), and morbid obesity. Additionally, his son had been recently diagnosed with severe COVID-19 after a recent trip to Vail, Colorado, 31 days ago, and they had contact in Mexico City 27 days before his admission. On arrival at the ER, the patient was afebrile, with clinical instability, hypotension (80/ 50 mmHg), tachycardia (140 b.p.m.), respiratory failure (30 b.p.m.), and severe oxygen desaturation (33%). The physical examination revealed a stuporous patient with pallor, diaphoresis, loud S2, bilateral lung crackles, swollen feet, and a body mass index (BMI) of 42.1 kg/m 2 . We started oxygen with a reservoir mask at 10 L/min, improving consciousness state, oxygen saturation (73%), and heart rate (HR) (110 b.p.m.).

The initial electrocardiogram (ECG) showed sinus tachycardia at 110 b.p.m., right axis deviation, QTc 471 ms, S1Q3T3, qR, STelevation in aVR and V1, and right ventricular overload ( Figure 1A) . A chest X-ray showed bilateral ground-glass opacity, and pulmonary infiltrates ( Figure 2) . A transthoracic echocardiogram revealed severe right ventricular dysfunction and hypokinesis, left ventricular ejection fraction (LVEF) of 80% by the Teicholz method, tricuspid annular plane systolic excursion (TAPSE) 9 mm, tricuspid regurgitation gradient of 28 mmHg, and pulmonary artery systolic pressure (PASP) of 48 mmHg (Video 1). Blood tests showed haemoglobin 14.6 g/dL (13.2-18.0 g/dL), 11.6 Â 10 3 /mL leucocytosis (4.5-11.0 Â 10 3 /mL), lymphocytes 700 per mm 3 (1000-4000 per mm 3 ), platelets 323 Â 10 3 /mL (150-420 Â 10 3 /mL), glucose 242 mg/dL (60-100 mg/dL), creatinine 1.3 mg/dL (0.7-1.3 mg/dL), hypoalbuminaemia 2.6 g/dL Biomarkers revealed a DD of 31.2 mcg/mL (<0.5 mcg/mL), BNP 101 pg/mL (<100 pg/mL), high-sensitivity troponin I (hs-cTnI) 49.7 ng/L (<2 ng/L) ( Figure 5 ), high-sensitivity protein C 22.68 mg/ dl (0.00-0.50 mg/dL), ferritin 304 ng/mL (20-250 ng/mL), and procalcitonin 0.55 ng/mL (<0.5 ng/mL). Based on risk factors, clinical presentation, a very high-risk pulmonary embolism severity index (PESI) score (239 points), and high-risk sPESI score (3 points), chest X-ray, biomarkers, and echocardiographic findings, we established a high-clinical suspicion of massive PE and communityacquired pneumonia.

We decided to commence treatment using alteplase with a 10 mg bolus, followed by 40 mg in 2 h and enoxaparin 80 mg BID. The computed tomography pulmonary angiography (CTPA) revealed a dilated main pulmonary artery (34 mm) and the presence of thrombus located in the right interlobar artery and the segmental branches of the superior left lobe and inferior left and right lobes ( Figure 3) . Unexpectedly, the lung parenchyma revealed a crazy-paving pattern, highly suggestive of severe COVID-19 pneumonia ( Figure 4) . Immediately after the 10 mg alteplase bolus, consciousness state, blood pressure (120/85 mmHg), HR (100 b.p.m.), and respiratory rate (25 b.p.m.) improved. Severe oxygen desaturation remained low (75%) despite using a reservoir oxygen mask at 10 l/min. Considering the thrombus burden and severe pneumonia, we decided to discontinue the 40 mg alteplase infusion and transfer the patient to the COVID-19 isolated ICU. To protect the patients and healthcare workers, we used a telepresence robot for daily interaction. The rapid nucleic acid amplification test for influenza A and B was negative. We collected samples following Center for Disease Control and Prevention (CDC) guidance (serum, and nasopharyngeal and oropharyngeal swab specimens). The patient received enoxaparin 80 mg BID, oral hydroxychloroquine 200 mg thrice in a day (TID), azithromycin 500 mg QD, IV ceftaroline 1 g QD, oral lopinavir/ritonavir 200/ 50 mg BID, and IV paracetamol 1 g TID.

On Day 2, the patient remained mostly stable. Upon follow-up examination, hs-cTnI and BNP increased, and D-dimer decreased ( Figure 5) . A chest X-ray reported a slight improvement of bilateral ground-glass opacity and pulmonary infiltrates. The nasopharyngeal and oropharyngeal swabs tested positive for SARS-CoV-2 by realtime reverse transcription-polymerase chain reaction (rRT-PCR) assay.

On Day 3, due to respiratory failure and diagnosis of acute respiratory distress syndrome (ARDS) we started invasive mechanical ventilation (FiO 2 70%, PEEP 16, and Kirby index of 105). The patient had hypotension as a side effect of sedation, which required transient inotropic support (norepinephrine). For the mechanical ventilation, we used A/C mode, with lung-protective ventilation using tidal volumes of 6 mL/kg predicted body weight and inspiratory pressure of 12 cmH 2 O. We maintained an initial respiratory rate (RR) 16 b.p.m., I:E relation of 1:1.5, and a constant PEEP of 16 cmH 2 O with decremental titration. We provided prone ventilation, and we did not use recruitment manoeuvres. Despite clinical worsening, the biomarkers continued to improve ( Figure 5) . We stopped hydroxychloroquine due to abnormal QTc (up to 560 ms) on follow-up ECG ( Figure 1B) . We administered three doses of tocilizumab 800 mg TID and continued full anticoagulation with enoxaparin. We maintained the norepinephrine support intermittently for nine days.

On Days 5 through 8, due to clinical worsening and the high viral load, we administered three doses of hyperimmune plasma each day, with improvement in ventilatory support (Kirby index of 187). On Day 9, we discontinued azithromycin, and after 14 days lopinavir/ ritonavir.

On Day 15, the patient had a fever, and we suspected a ventilatorassociated pneumonia. We obtained a tracheal aspirate culture, which showed Klebsiella pneumoniae, and we started meropenem for 7 days. After 20 days, clinical, ventilatory, and laboratory parameters improved ( Figure 5) , and we successfully removed the patient from mechanical ventilation.

The patient remained in hospital with episodes of delirium and intermittent dry cough, with oxygen saturation of 98% and ongoing enoxaparin 80 mg BID. A repeat rt-PCR swab was negative for SARS-CoV-2 and negative anti-cardiolipin IgM, IgG, Beta-2-glycoprotein antibodies, and phosphatidylserine IgA, IgM, and IgG were reported. We did not perform lower limb ultrasound and further CTPA due to critical illness.

After 29 days, the patient was discharged with propranolol 10 mg TID, losartan 50 mg BID, amlodipine 5 mg QD, and rivaroxaban 20 mg QD. In a telemedicine follow-up office visit 15 days later, the patient remained asymptomatic and was undergoing physical rehabilitation. A follow-up echocardiogram performed four months after initial presentation showed improvement in right ventricular size and function, with a TAPSE of 23 mm (Video 2). 

The main observations of this case were as follows: firstly, after thrombolysis and anticoagulation, DD measurements improved. Secondly, upon admission BNP was discordantly low despite severe right ventricular dysfunction, likely related to a short time between the onset of symptoms and admission to hospital; in the next 24 h BNP correlated with the presence and degree of right ventricular dysfunction and higher hs-cTnI measurements, suggesting type 2 myocardial infarction 3 ( Figure 5) . Thirdly, this case was a clinical challenge because acute PE and COVID-19 pneumonia overlapped. Finally, this case represents-to our knowledge-the first description of biomarkers (DD, BNP, hs-cTnI) in scenarios involving COVID-19 pneumonia and PE.

Since the first clinical description, 4 abnormal DD measurements and age have been related to increased mortality and a high prevalence of thrombotic events in COVID-19. 5,6 Patients with severe COVID-19 disease are at high-risk of thromboinflammation since they have proinflammatory risk factors and cardiopulmonary comorbidities related to inflammation. 7 The SARS-CoV-2 infection leads to a cytokine storm, inducing endothelial activation, cell damage, increased platelet aggregation, thrombi sensitivity, arterial inflammation, as well as disruption of vulnerable plaques. 8, 9 Interleukin-6 (IL-6) induces the expression of several prothrombotic factors and dysregulation of antithrombin III, protein S, and thrombomodulin. 9, 10 Additionally, it could activate immunothrombosis, another thrombosis mechanism. 10 All these mechanisms can induce diffuse microangiopathy with micro and macro thrombosis. 11 Also, SARS-CoV-2 may predispose to both venous and arterial thrombosis secondary to antiphospholipid antibodies, 12, 13 hypoxia, immobilization, and diffuse intravascular coagulation. 14 Among the common complications observed in deceased patients with severe COVID-19, 7 venous thromboembolism (VTE) has emerged as a critical and frequent complication. 9 Currently, we do not have strong evidence of the overall incidence and recommendations for in-hospital anticoagulation in patients with PE. 9, 11, 15 However, the available evidence suggests a frequency of 25% to 27% in ICU patients 14, 16 and imaging has demonstrated both unilateral and bilateral thrombus (small branches, segmental, lobar, and main pulmonary artery). 5, 17, 18 DD measurements seem to be an available test to identify high-risk groups of VTE 14, 18 and patients that need different doses of enoxaparin [low (0.6 mg/kg/12 h) 18 or standard treatment 17 ] .

In this complicated case with overlapping severe COVID-19 pneumonia and PE, the clinical presentation suggesting massive PE drove the decision to use systemic thrombolysis. We supported the highclinical suspicion of massive PE based on sudden dyspnoea, chest pain, presyncope, a fall in blood pressure, ECG changes, echocardiographic findings, as well as signs of deep venous thrombosis. We decided to interrupt the alteplase infusion based on thrombus burden, which was lower than expected considering the clinical presentation of massive PE, a high rate of bleeding (16%) in populations with respiratory failure 15 and lacking recommendations in severe COVID-19 disease. 9,15 A relevant observation is that after the alteplase bolus, an immediate significant clinical improvement suggesting reperfusion appeared. This result could represent the effectiveness and safety of 10 mg or 5 mg alteplase bolus to initiate fibrinolysis in ST-elevation myocardial infarction 19 and left atrial thrombus, respectively. 20 Also, another low dose of alteplase (30 mg) was safe and effective in submassive PE patients, 21 and an alteplase bolus of 10 mg followed by a 2-h 40 mg infusion in ARDS 22 and pulmonary vascular phenotype COVID-19 patients. 23 After thrombolysis, in the first 96 h, enoxaparin achieved a significant decrease in DD measurements ( Figure 5 ). Considering the clinical condition, the evidence suggesting prophylactic anticoagulation failure, 24 and the high risk of recurrence (individual, COVID-19, ICU, and hospital stay), we sustained the subcutaneous therapeutic anticoagulation without bleeding complications during the in-hospital stay. At admission, the exceptionally high DD levels observed suggested hyper-inflammation, hypercoagulability, and an actual thrombotic disease, possibly induced by cellular activation triggered by the virus, 25 and resemble the extremely high values encountered in COVID-19 related acute or pulmonale, 26 as well as thrombotic events in cerebral 27 and coronary circulation. 28 Additionally, we should never ignore abnormal or extremely elevated DD levels 29 in COVID-19, since it is the expression of the coagulation system and fibrinolysis activity, suggesting high-risk of acute thrombosis. 29 Although, in our case, the extremely elevated DD levels could be explained by the association of severe COVID-19 and VTE, we cannot exclude the possibility of subclinical cancer. 30 After anticoagulation therapy, reduced DD levels suggest anticoagulation effectiveness 16 ( Figure 5 ). Preliminary evidence suggests mortality benefit from anticoagulation in severe COVID-19 disease, 31 including anti-inflammatory mechanisms. 32 Upon admission, the measurement of hs-cTnI suggested myocardial injury with a subsequent increase (likely due to type 2 myocardial infarction) still detectable until 96 h later 33 ( Figure 5) , similar to the behaviour observed in PE patients. 33 The initial therapeutic approach decreased the expression of hs-cTnI, which is historically related to poor in-hospital outcomes in COVID-19 15 and non-COVID-19 patients. 3 Another interesting finding was the initial borderline BNP measurements despite severe RVD. B-type natriuretic peptide concentration might seem discordantly low in flash pulmonary oedema (1 h), acute pulmonary oedema secondary to acute mitral regurgitation, immunologic myopericarditis with predominantly right ventricular involvement 34 and submassive PE. 35 In these settings, BNP gene expression may have had insufficient time between the initial trigger of increased ventricular wall stress and the measurement of BNP concentrations, since the half-life of BNP is 23 min and 2 h are required for its full expression. 35 The mechanism of massive PE and initial almost normal BNP value was the immediate patient presentation after symptom onset. 35 This case identifies another clinical condition characterized by severe ventricular dysfunction and discordantly low BNP. BNP measurements in the next 24 h correlated with the right ventricular dysfunction stage and reperfusion, 36 and serial measurements were useful in assessing the success of thrombolysis and anticoagulation. 36 Despite worsening respiratory effects and mechanical ventilation, BNP remained below 50 pg/mL until discharge ( Figure 5) .

Non-COVID-19 pneumonia and PE have a frequent association (65.6%) that increases mortality. 37 This patient with risk factors for PE and risk factors for severe COVID-19 disease had both acute events at home. Current evidence regarding COVID-19 pneumonia and PE comes from in-hospital series and case reports. 5, 14, 17, 18, 26, [38] [39] [40] Therefore, the clinical presentation of an acute PE in the setting of Figure 5 Biomarker values on admission and their immediate reduction following anticoagulation and thrombolytic treatment. We also demonstrate biomarkers in-hospital follow-up, the IL-6 behaviour, and the therapeutic approach during the in-hospital stay. D-dimer red line, B-type natriuretic peptide blue line, Hs-cTnI yellow line, and IL-6 purple line. HCQ, hydroxychloroquine; LMWH, low-molecular-weight heparin; rtPA, recombinant tissue plasminogen activator; TCL, tocilizumab.

Systemic thrombolysis and anticoagulation in severe COVID -19 severe COVID-19 pneumonia in an outpatient is not clear. Recently, in a case series of PE patients with risk factors, the clinical presentation was characterized by persistence or worsening of respiratory symptoms with increasing oxygen requirements. Besides, DD levels were several-fold higher than the normal upper threshold. 2 Recently, systemic thrombolysis in one massive PE patient with COVID-19 induced bleeding complications as the cause of mortality; 2 however, the thrombolytic regimen and the bleeding complication were not described. Initial clinical behaviour in this case was similar to that observed in non-COVID-19 submassive and massive PE patients. 41, 42 Considering CTPA findings, the mechanisms of pulmonary hypertension and right ventricular dysfunction could be multifactorial, including pulmonary thrombi, hypoxic pulmonary vasoconstriction, 43 and possible pulmonary microthrombi. 23,44 Also, SARS-CoV-2 direct downregulation of ACE2 may result in unopposed angiotensin II accumulation and local renin-angiotensin-aldosterone system (RAAS) activation, increasing pulmonary vasoconstriction. 45 Finally, the favourable outcome was related to early PE diagnosis and a multimodal therapeutic approach, including respiratory support, fibrinolysis activation, coagulation system inhibition, antivirals, antibiotics, a monoclonal antibody, and hyperimmune plasma ( Figure 5) . We also need current and robust evidence to identify if we need a different thrombolytic regimen to those currently recommended. 26, 46 Conclusion Physicians in the ER should be warned about high or extremely elevated DD measurements and severe oxygen desaturation, as possible risk markers of severe COVID-19 pneumonia in patients with highclinical suspicion of PE. Also, they should be aware of this 2-h lag period before the onset of BNP increase to avoid underdiagnosing right ventricular dysfunction. 35 Finally, we suggest CTPA before starting immediate reperfusion in a severe COVID-19 patient with highclinical suspicion of massive PE. 46

Héctor Betancourt del Campo is a Cardiology Fellow in training and has an Internal Medicine PhD. He actually practices echocardiography, heart failure, haemodynamics, and electrophysiology in Zambrano Hellion Hospital, TecSalud of Tecnologico de Monterrey. He is interested in becoming an Electrophysiology Fellow next year.

Supplementary material is available at European Heart Journal -Case Reports online.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

The author/s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidelines.

Genomewide association study of severe Covid-19 with respiratory failure

Acute pulmonary embolism in COVID-19 disease: preliminary report on seven patients

Recommendations for institutions transitioning to high-sensitivity troponin testing

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

COVID-19 complicated by acute pulmonary embolism

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Acute infection and myocardial infarction

COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies

Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians

The science underlying COVID-19: implications for the cardiovascular system

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

COVID-19 complicated by acute pulmonary embolism and right-sided heart failure

Findings of acute pulmonary embolism in COVID-19 patients

Therapeutic fibrinolysis

Low-dose thrombolysis for the management of left atrial thrombus formation during percutaneous mitral valve repair

References 21 to 46 are available in Supplementary material online

Funding: none declared.